What is the enterprise value (EV) for Iovance Biotherapeutics, Inc. (IOVA)?

The enterprise value (EV) for IOVA stock is $5.70B.

Iovance Biotherapeutics (IOVA) Enterprise Value: History & Chart

Compare

Iovance Biotherapeutics, Inc.(IOVA)

Biotechnology · San Carlos, CA

$13.12-1.04 (-7.31%)

Delayed quote: Oct 6, 2026, 12:10 PM EDT

Compare

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.

San Carlos, CA

975 employees

www.iovance.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Frederick G. Vogt

View full financials

NAME	MARKET CAP	ENTERPRISE VALUE (EV)
Iovance Biotherapeutics, Inc. (IOVA)	$5.86B	$5.70B
GRAIL Inc. (GRAL)vs ›	$5.96B	$5.99B
Ligand Pharmaceuticals Incorporated (LGND)vs ›	$5.98B	$6.11B
Kiniksa Pharmaceuticals International, plc (KNSA)vs ›	$5.77B	$5.60B
CG Oncology Inc. (CGON)vs ›	$5.76B	$5.75B
MiniMed Group, Inc. Common Stock (MMED)vs ›	$5.55B	$5.40B
RadNet, Inc. (RDNT)vs ›	$5.54B	$6.99B
Rhythm Pharmaceuticals, Inc. (RYTM)vs ›	$6.44B	$6.37B
PTC Therapeutics, Inc. (PTCT)vs ›	$5.38B	$5.02B
Doximity, Inc. (DOCS)vs ›	$5.34B	$5.07B

NAME

MARKET CAP

ENTERPRISE VALUE (EV)

Iovance Biotherapeutics, Inc. (IOVA)

$5.86B

$5.70B

GRAIL Inc. (GRAL)vs ›

$5.96B

$5.99B

Ligand Pharmaceuticals Incorporated (LGND)vs ›

$5.98B

$6.11B